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The antiphospholipid syndrome is an acquired autoimmune disorder characterized by thrombotic events, miscarriages, and elevated levels of antiphospholipid antibodies. 1 The syndrome is described as secondary if associated with autoimmune diseases, such as lupus erythematosus or rheumatoid arthritis, and as primary if not. The most common thrombotic manifestation of the antiphospholipid syndrome is venous thrombosis, which is usually manifested as deep-vein thrombosis, with or without pulmonary embolism, but arterial thrombosis can also occur, particularly in the context of transient cerebral ischemia or stroke. In rare instances, extensive microvascular thrombosis leads to multiorgan failure involving the brain, lungs, and kidneys, a condition known as catastrophic antiphospholipid syndrome. 2 The mechanisms by which antiphospholipid antibodies cause thrombosis are uncertain (Fig. 1) . 4 Current management strategies focus on prevention with aspirin and in some cases with immunomodulatory therapy; once an episode has occurred, treatment includes aspirin, anticoagulants, or both. 5 Even in the absence of catastrophic disease, the antiphospholipid syndrome can be associated with a vasculopathy that has been best documented in studies of the brain and kidneys. Cognitive deficits, which are more common in patients with the antiphospholipid syndrome than in controls, are associated with lesions in white matter on brain imaging that are suggestive of vasculopathy. 6 The examination of kidney biopsy specimens has shown that renal dysfunction in patients with primary antiphospholipid syndrome is associated with evidence of thrombotic microangiopathy involving small and medium-sized vessels. 7 The limited understanding of the pathophysiology of this vasculopathy has hampered the identification of effective therapies and has left experts divided about what constitutes the most effective management. Some experts suggest aspirin for patients with cerebral ischemia, with or without lesions in white matter, and recommend increasing the intensity of anticoagulation therapy in patients with clinical progression. 8 In patients with catastrophic antiphospholipid syndrome, these treatments are often combined with plasmapheresis, glucocorticoids, and the intravenous administration of immunoglobulin, with or without rituximab. 2 In this issue of the Journal, Canaud and colleagues provide new insights into the mechanism of vasculopathy in the antiphospholipid syndrome. 3 Using biopsy specimens from the kidney obtained from patients with nephropathy, with or without the antiphospholipid syndrome, and from controls without nephropathy, the authors show that antiphospholipid antibodies up-regulate the mammalian target of rapamycin complex (mTORC) pathway in renal vascular endothelial cells. The authors hypothesize that the activation of these signaling pathways, which regulate cell growth, proliferation, and survival (Fig. 1) , triggers vasculopathy. The article provides additional support for this hypothesis by providing data that link enhanced allograft survival with the use of sirolimus (formerly known as rapamycin) in patients with the The antiphospholipid syndrome is an acquired autoimmune disorder characterized by persistent elevation in levels of antiphospholipid antibodies, thrombosis, and in some cases vasculopathy. Although multiple mechanisms have been implicated in the pathogenesis of thrombosis, the cause of vasculopathy remains elusive. In this issue of the Journal, Canaud and colleagues 3 hypothesize that antiphospholipid antibodies, in binding to vascular endothelial cells in the kidneys, brain, or other organs, activate the signaling pathway of the mammalian target of rapamycin (mTOR). In response to extracellular and intracellular signals in the phosphoinositide 3-kinase (PI3K)-AKT pathway, the mTOR pathway regulates cell growth, proliferation, and survival. The mTOR enzyme is a component of two complexes, mTORC1 and mTORC2. The activity of mTORC1 is regulated by a subunit of the regulatory-associated protein of mTORC1 (RAPTOR), whereas the activity of mTORC2 is regulated by a subunit of the rapamycin-insensitive companion of mTOR (RICTOR). However, the two pathways are interconnected. Aspirin and anticoagulants are used for the prevention and treatment of thrombosis in patients with antiphospholipid syndrome. Sirolimus, which inhibits the mTORC1 pathway, has the potential to attenuate vasculopathy. antiphospholipid syndrome who underwent renal transplantation. The activation of the mTORC pathways has also been implicated in the pathogenesis of restenosis after percutaneous coronary intervention, 9 a finding that prompted the development of sirolimus-eluting coronary stents. 10 The limited success of antithrombotic therapy in patients with vasculopathy associated with the antiphospholipid syndrome and the unproven benefit of current immunomodulatory treatments for catastrophic antiphospholipid syndrome highlight the need for improvements. By targeting pathways such as the mTORC pathway, which appears to be causative, sirolimus or other mTORC inhibitors may become the preferred treatment. However, independent confirmation is needed before such an approach is adopted. The clinical outcome data provided by Canaud and colleagues are observational and may be subject to bias, and since antiphospholipid antibodies are heterogeneous, it is possible that only a subset of these antibodies targets the mTORC pathway. Nonetheless, if the authors' findings are confirmed, patients with mTORCpathway-directed antiphospholipid antibodies may benefit from sirolimus, not only to improve renal allograft survival but also to prevent the development of vasculopathy -goals that require exploration in clinical trials.
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